Background: The accumulation of misfolded tau proteins, an Alzheimer's disease (AD) hallmark, starts decades before the emergence of cognitive decline and clinical diagnosis. Autopsy studies support a predictable progression of tau pathology through large-scale systems. However, less is known about the specific progression patterns. The use of connectomic metrics could enhance our understanding of the characteristics of pathology spread. We examined the spatiotemporal relationships of cortical tau accumulation using network motifs, directed graph metrics, which can reveal the underlying mechanisms governing the pathology progression routes in preclinical and clinical AD.
Methods: We used longitudinal tau-PET data (1-year follow-up) from 40 adults with normal cognitive functioning and 33 adults with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative (ADNI-3) (Table 1). We used individual and group-level whole-brain voxel-wise graph theory and motifs networks analyses to investigate AD-related tau pathology directional spreading (Figure 1a). Directional relations are established by using group-level association matrices and by assessing differences in between-voxels temporal relations (Time1-Time2; FDR-corrected, p<0.001) (Figure 1b). Then, the resulting association matrix representing the human connectome is decomposed into motif networks, which are three-node triangular fundamental relations (i.e., exact copies of every possible motif is searched at the voxel-level) (Figure 1c). Finally, between-group visual comparisons of each motif reveal similarities and differences in dominant pathology spreading patterns in preclinical vs. clinical AD stages (Figure 1d).
Results: Our results support that unidirectional and serial network motifs are behind misfolded tau protein spreading in AD (Figure 2). Feed-forward loops, cascade, and regulated mutual networks drive tau propagation in medial and lateral temporal and medial prefrontal regions early in the disease. Through the disease, spread out from one region to another (i.e., fan out and regulating mutual networks) is a common characteristic of tau progression.
Conclusion: Our results suggest that the progression of toxic tau through the brain systems occurs mainly in a unidirectional and serial manner. AD is considered a dysconnectivity disease. Thus, serial motifs could indicate biological relations arising on a sequential spatiotemporal scale. Future developments will examine the role of amyloid accumulation in tau progression in the context of AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.088834 | DOI Listing |
Adv Sci (Weinh)
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
β-secretase (BACE1) is instrumental in amyloid-β (Aβ) production, with overexpression noted in Alzheimer's disease (AD) neuropathology. The interaction of Aβ with the receptor for advanced glycation endproducts (RAGE) facilitates cerebral uptake of Aβ and exacerbates its neurotoxicity and neuroinflammation, further augmenting BACE1 expression. Given the limitations of previous BACE1 inhibition efforts, the study explores reducing BACE1 expression to mitigate AD pathology.
View Article and Find Full Text PDFActa Neuropathol Commun
January 2025
Department of Biological Sciences, Purdue University, 915 Mitch Daniels Blvd, West Lafayette, IN, USA.
Dementia refers to an umbrella phenotype of many different underlying pathologies with Alzheimer's disease (AD) being the most common type. Neuropathological examination remains the gold standard for accurate AD diagnosis, however, most that we know about AD genetics is based on Genome-Wide Association Studies (GWAS) of clinically defined AD. Such studies have identified multiple AD susceptibility variants with a significant portion of the heritability unexplained and highlighting the phenotypic and genetic heterogeneity of the clinically defined entity.
View Article and Find Full Text PDFNeurotherapeutics
January 2025
Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada. Electronic address:
Amyloidogenic protein aggregation is a pathological hallmark of Alzheimer's Disease (AD). As such, this critical feature of the disease has been instrumental in guiding research on the mechanistic basis of disease, diagnostic biomarkers and preventative and therapeutic treatments. Here we review identified molecular triggers and modulators of aggregation for two of the proteins associated with AD: amyloid beta and tau.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
First Operating Room, The First Hospital of Jilin University, Changchun, China. Electronic address:
Background: Certain peripheral proteins are believed to be involved in the development of Alzheimer's disease (AD), but the roles of other new protein biomarkers are still unclear. Current treatments aim to manage symptoms, but they are not effective in stopping the progression of the disease. New drug targets are needed to prevent Alzheimer's disease.
View Article and Find Full Text PDFNeuroscience
January 2025
Departamento de Genómica, Instituto de Investigaciones Biológicas Clemente Estable, MEC, Av. Italia 3318, Montevideo, CP 11600, Uruguay; Departamento de Biología Celular y Molecular, Facultad de Ciencias, Universidad de la República, Iguá, Montevideo, 4225, CP 11400, Uruguay. Electronic address:
Local protein synthesis (LPS) in axons is now recognized as a physiological process, participating both in the maintenance of axonal function and diverse plastic phenomena. In the last decades of the 20th century, the existence and function of axonal LPS were topics of significant debate. Very early, axonal LPS was thought not to occur at all and was later accepted to play roles only during development or in response to specific conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!